Literature DB >> 19377018

Paraneoplastic limbic encephalitis.

Alison R Foster1, Jason P Caplan.   

Abstract

BACKGROUND: Paraneoplastic limbic encephalitis (PLE) is a syndrome characterized by the development of neuropsychiatric symptoms due to a misdirected tumor-activated antibody response that damages host neural tissue. Definitive treatment relies on the identification and ablation of the underlying tumor. Few publications describe the management of psychiatric symptoms associated with PLE.
OBJECTIVE: Given the plethora of neuropsychiatric symptoms that may mimic primary psychiatric illness, and the possibility that PLE may herald a life-threatening malignancy, it is important that psychiatrists become familiar with this condition.
METHOD: The authors review and discuss the consensus literature on the various aspects of PLE. DISCUSSION: In this review, authors summarize proposed mechanisms and treatments of PLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377018     DOI: 10.1176/appi.psy.50.2.108

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  4 in total

Review 1.  Autoimmune-mediated encephalitis.

Authors:  Philippe Demaerel; Wim Van Dessel; Wim Van Paesschen; Rik Vandenberghe; Koen Van Laere; Jennifer Linn
Journal:  Neuroradiology       Date:  2011-01-27       Impact factor: 2.804

2.  A case of paraneoplastic limbic encephalitis associated with ovarian teratoma and N-Methyl-d-Aspartate receptor antibodies.

Authors:  Lynn Takeshita; Diana Domnitei; Junji Takeshita
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Limbic encephalitis as the presenting symptom of oesophageal adenocarcinoma: another cancer to search?

Authors:  Renata Barbosa Menezes; Adson Freitas de Lucena; Fernanda Martins Maia; Antônia Rosivalda Teixeira Marinho
Journal:  BMJ Case Rep       Date:  2013-04-16

4.  [Diagnostic work-up and treatment of acute psycho-organic syndrome].

Authors:  C Thomas; M Driessen; V Arolt
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.